Patents by Inventor Michael Chorev
Michael Chorev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050004037Abstract: The present invention relates to a pharmaceutical composition comprising as an effective ingredient an oligopeptide identical or analogous to the C-terminal portion of OGP, having stimulatory activity on the production of hematopoietic cells. Preferred oligopeptides that are used are Tyr-Gly-Phe-Gly-Gly, Tyr-Gly-Phe-His-Gly, Gly-Phe-Gly-Gly or Met-Tyr-Gly-Phe-Gly-Gly. More specifically, these oligopeptides enhance the engraftment of bone marrow transplants, hemopoietic reconstruction, bone marrow re-population and peripheral stem cell mobilization, preferably after chemotherapy or irradiation. The invention further provides methods of treatment and for using these oligopeptides in the preparation of pharmaceutical compositions.Type: ApplicationFiled: January 29, 2004Publication date: January 6, 2005Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Itai Bab, Michael Chorev, Arye Shteyer, Andras Muhlrad, Nura Mansur, Olga Gurevitch, Zvi Greenberg, Sergio Rosini, Silvia Trasciatti, Mario Petrini
-
Publication number: 20030069175Abstract: Cyclic to Synthetic pseudopeptide derivatives of osteogenic growth polypeptide (OGP) and OGP(10-14) which are capable of enhancing bone cell proliferation and bone formation. Pharmaceutical composition comprising as active ingredient at least one pseudopeptide derivative of the invention and to the use of these pseudopeptide derivatives in the preparation of a pharmaceutical composition for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation in osteopenic pathological conditions, repairing fractures, healing wounds, grafting of intraosseous implants, reversing bone loss in osteoporosis and other conditions requiring enhanced bone cells formation.Type: ApplicationFiled: September 27, 2002Publication date: April 10, 2003Inventors: Itai Bab, Dan Gazit, Chen Yu-Chen, Andras Muhlrad, Arie Shteyer, Michael Chorev
-
Patent number: 6538025Abstract: This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: August 31, 2001Date of Patent: March 25, 2003Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd., Yissum Research Development Company of the Hebrew University of JerusalemInventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B.H. Youdim
-
Publication number: 20020188020Abstract: This invention is directed to compounds of the following formula: 1Type: ApplicationFiled: August 31, 2001Publication date: December 12, 2002Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B.H. Youdim
-
Patent number: 6479460Abstract: The invention relates to synthetic pseudopeptide derivatives of osteogenic grog polypeptide (OGP) and OGP(10-14) which may be linear or cyclic, and which are capable of enhancing bone cell proliferation and bone formation. Further, the present invention relates to pharmaceutical composition comprising as active ingredient at least one pseudopeptide derivative of the invention and to the use of these pseudopeptide derivatives in the preparation of a pharmaceutical composition for stimulating the formation of osteoblastic or fibroblastic cells, enhancing bone formation in osteopenic pathological conditions, repairing fractures, healing wounds, grafting of intraosseous implants, reversing bone loss in osteoporosis and other conditions requiring enhanced bone cells formation.Type: GrantFiled: September 10, 1998Date of Patent: November 12, 2002Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Itai Bab, Dan Gazit, Chen Yu-Chen, Andras Muhlrad, Arie Shteyer, Michael Chorev
-
Patent number: 6462222Abstract: This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is 0 or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R1 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome. Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: August 31, 2001Date of Patent: October 8, 2002Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.Inventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B. H. Youdim
-
Patent number: 6303650Abstract: This invention is directed to compounds of the following formula wherein when a is O, b is 1 or 2; when a is 1, b is 1, m is from 0-3 X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADC), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: June 18, 1999Date of Patent: October 16, 2001Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Technion Research and Development Foundation, Ltd., Teva Pharmaceutical Industries, Ltd.Inventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B. H. Youdim
-
Patent number: 6251938Abstract: This invention is directed to compounds of the following formula: wherein m is from 0-4; X is O or S; Y is halogeno; R1 is hydrogen or C1-4 alkyl; R2 is hydrogen, C1-4 alkyl or optionally substituted propargyl; and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 cycloalkyl or C6-12 aralkyl, R5 is hydrogen or C1-4 alkyl; and pharmaceutically acceptable salts thereof, provided that when X is O, R2 is optionally substituted propargyl. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: June 18, 1999Date of Patent: June 26, 2001Assignees: Teva Pharmaceutical Industries, Ltd.,, Technion Research and Development Foundation, Ltd.,, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B. H. Youdim
-
Patent number: 5814610Abstract: The invention relates to biochemically pure oligopeptides having stimulatory activity on osteoblastic and/or fibroblastic cells having a molecular weight between 200 and 2,000. Preferred oligopeptides according to the invention comprise the amino acid sequences Tyr-Gly-Phe-His-Gly (SEQ.ID.No.2) and Gly-Phe-Gly-Gly (SEQ.ID.No.3). The invention further relates to pharmaceutical compositions for the stimulation of formation of osteoblastic or fibroblastic cells, enhanced bone formation in osteogenic pathological conditions, fracture repair, healing of wounds, intraosseous implants and bone supplementation, or other conditions requiring enhanced bone formation cells comprising a therapeutically effective amount of an oligopeptide according to the invention.Type: GrantFiled: January 5, 1996Date of Patent: September 29, 1998Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Itai Bab, Andras Muhlrad, Michael Chorev, Arie Shteyer, Zvi Greenberg, Nura Mansur
-
Patent number: 5747456Abstract: A method of promoting bone formation in a human patient, which includes the step of administering continuously to the patient parathyroid hormone or its agonist for a period of at least one month at a dosage between 10 and 400 units/24 hrs. Also disclosed are novel parathyroid hormone agonists.Type: GrantFiled: September 30, 1996Date of Patent: May 5, 1998Assignee: Beth Israel Deaconess Medical CenterInventors: Michael Chorev, Michael Rosenblatt
-
Patent number: 5717062Abstract: Cyclic analogs of PTH and PTHrP wherein a disulfide or amide bond links the side chains of residues A.sub.13 and A.sub.17, A.sub.26 and A.sub.30, or A.sub.13 and A.sub.17 and A.sub.26 and A.sub.30.Type: GrantFiled: June 7, 1995Date of Patent: February 10, 1998Assignee: Beth Israel Hospital AssociationInventors: Michael Chorev, Michael Rosenblatt
-
Patent number: 5461034Abstract: A biochemically pure polypeptide(s), termed osteogenic growth polypeptide (OGP), which exhibits stimulatory effects on osteoblastic cells, in vivo bone formation and hemopoietic reconstruction. OGP, identified from regenerating bone marrow, has an amino acid sequence ofAla-Leu-Lys-Arg-Gln-Gly-Arg-Thr-Leu-Tyr-Gly-Phe-Gly-Gly.Type: GrantFiled: June 18, 1993Date of Patent: October 24, 1995Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Gideon A. Rodan, John W. Jacobs, Mohinder K. Sardana, Dan Gazit, Michael Chorev, Andras Muhlrad, Arye Shteyer, Nura Mansur, Zvi Greenberg, Shimon Slavin, Olga Gurevitch, Itai A. Bab
-
Patent number: 5242680Abstract: Novel thiol-reactive maleimido-based radiolabeling reagents are disclosed which are useful for binding and receptor studies and assays. The reagents are also useful as diagnostic imaging agents, and as radiotherapeutic drugs.Type: GrantFiled: August 23, 1991Date of Patent: September 7, 1993Assignee: Merck & Co., Inc.Inventor: Michael Chorev
-
Patent number: 5217999Abstract: A method of inhibiting cell proliferation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition comprising, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutically acceptable salt thereof, which is a substituted styrene compound which can also be a naphthalene, an indane or a benzoxazine; including nitrile and molononitrile compounds, and pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of such compound.Type: GrantFiled: March 24, 1992Date of Patent: June 8, 1993Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Alexander Levitzki, Chaim Gilon, Michael Chorev, Aviv Gazit
-
Patent number: 5149779Abstract: Peptide analogues of human humoral hypercalcemic factor (hHCF) that contain a lactam bridge act as inhibitors of the naturally occurring peptide. A lactam bridge between Lys and Asp situated five residues (inclusive) apart confers rigidity to that region of the peptide, and enhances the helical nature and metabolic stability of the peptide analogue.Type: GrantFiled: July 26, 1990Date of Patent: September 22, 1992Assignee: Merck & Co., Inc.Inventors: Michael Chorev, Eli Roubini
-
Patent number: 5093233Abstract: The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone (PTH), wherein Lys.sup.13 is substituted to increase the biological activity of the PTH analogues. Thus, there are disclosed peptides having the formulae:PTH(7-34)NH.sub.2 ;[Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[Nle.sup.8,18, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ; and,desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(8-34)NH.sub.2wherein Lys.sup.13 is modified in the epsilon-amino acid group by N,N-diisobutyl or 3-phenylpropanoyl.Type: GrantFiled: April 25, 1990Date of Patent: March 3, 1992Assignee: Merck & Co., Inc.Inventors: Michael Rosenblatt, Eliahu Roubini, Michael Chorev, Ruth F. Nutt
-
Patent number: 5087561Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 or Lys.sup.11 is modified on the epsilon-amino group by biotin so as to produce HCF analogues which can inhibit the action of HCF.Type: GrantFiled: June 28, 1990Date of Patent: February 11, 1992Assignee: Merck & Co., Inc.Inventors: Michael Rosenblatt, Michael Chorev, Eliahu Roubini, Ruth F. Nutt, Le T. Duong
-
Patent number: 5087562Abstract: The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys.sup.13 is modified so as to produce HCF analogues which can inhibit the action of HCF.Type: GrantFiled: April 25, 1990Date of Patent: February 11, 1992Assignee: Merck & Co., Inc.Inventors: Michael Rosenblatt, Eliahu Roubini, Michael Chorev, Ruth F. Nutt
-
Patent number: 5001223Abstract: The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone wherein Phe.sup.7 is substituted by NMePhe, D-Phe, desamino Phe, or Met.sup.8 is substituted by NMeMet.Type: GrantFiled: March 2, 1989Date of Patent: March 19, 1991Assignee: Merck & Co., Inc.Inventors: Michael Rosenblatt, Lynn H. Caporale, Michael Chorev
-
Patent number: RE38761Abstract: A method of inhibiting cell proliferation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition comprising, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutically acceptable salt thereof, which is a substituted styrene compound which can also be a naphthalene, an indane or a benzoxazine; including nitrile and molononitrile compounds, and pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of such compound.Type: GrantFiled: October 14, 1994Date of Patent: July 19, 2005Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Alexander Levitzki, Chaim Gilon, Michael Chorev, Aviv Gazit